Protocol Ledger

NCT05103657 · Phase II · COMPLETED

A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder

Interventional Phase II clinical trial protocol NCT05103657 sponsored by Boehringer Ingelheim in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-07 Enrollment: 318 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05103657
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)318 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05103657
Protocol FieldVerified Registry Value
NCT IdentifierNCT05103657
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment318 participants (ACTUAL)
Registered Start Date2021-12-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05103657
Hospital Research SiteLocationSite Profile
Artemis Institute for Clinical ResearchRiverside, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI